CYP4F2 and steatosis: We analyzed the expression of the CYP4A11, CYP4F2 and CYP2E1 in patients with steatosis, steatohepatitis, cirrhosis, and HCC and found that both CYP4A11 mRNA and protein increase in the progression of MASLD [52], while CYP4F2, the primary P450 in the metabolism of AA to produce 20-HETE, decreases in MASLD progression.